Moreover, beyond HE treatment, Horvath et al. recently observed LOLA’s positive impact on enhancing the microbiome and beneficial metabolomic changes, such as IGF-1 levels, in liver disease patients27. This evidence concerns the gene IGF1 and hereditary elliptocytosis.